BTAI
BioXcel Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$0.88-0.54%
Price as of Jul 20, 2026
BTAI profitability
BioXcel Therapeutics, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 27.8%
- EBITDA margin
- -8509.3%
- EBIT margin
- -7395.0%
- Net margin
- —
- Free cash flow margin
- -8438.4%
Returns
- Return on equity
- 71.4%
- Return on assets
- -221.4%
- Return on invested capital
- 957.1%
- Asset turnover
- 0.02x
Cash efficiency
- Cash from operations
- -$57.4M
- Cash per share
- $0.63
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.